{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:26:52Z","timestamp":1794673612863,"version":"4.9.1"},"reference-count":19,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3,1]]},"abstract":"<jats:p>BACKGROUND. The measles-mumps-rubella vaccine has been associated with immune thrombocytopenia purpura in 2 small studies.<\/jats:p>\n               <jats:p>METHODS. By using the Vaccine Safety Datalink, we identified measles-mumps-rubella\u2013vaccinated children aged 1 to 18. A case of immune thrombocytopenia purpura was defined as a patient with a platelet count of \u226450000\/\u03bcL with clinical bleeding and normal red and white blood cell indices. The immune thrombocytopenia purpura incidence rates during exposed (42 days after vaccination) and unexposed time periods were determined. A retrospective cohort of vaccinated children was used to determine incident rate ratios for children aged 1 to 18 years, 12 to 23 months, and 12 to 15 months.<\/jats:p>\n               <jats:p>RESULTS. A total of 1036689 children received 1107814 measles-mumps-rubella vaccinations; there were 259 confirmed patients with immune thrombocytopenia purpura. Because only 5 exposed cases occurred after age 2, analyses were limited to children aged 12 to 23 months. Exposed patients aged 12 to 23 months had lower median platelet counts than those who were unexposed and had similar median duration of illness (11 vs 10 days). The incident rate ratio was highest for children aged 12 to 15 months at 7.10. The incident rate ratio for boys aged 12 to 15 months was 14.59, and the incident rate ratio for girls in the same age group was 3.22. Seventy-six percent of immune thrombocytopenia purpura cases in children aged 12 to 23 months were attributable to measles-mumps-rubella vaccination. This vaccine causes 1 case of immune thrombocytopenia purpura per every 40000 doses.<\/jats:p>\n               <jats:p>CONCLUSION. Measles-mumps-rubella vaccine that is given in the second year of life is associated with an increased risk of immune thrombocytopenia purpura.<\/jats:p>","DOI":"10.1542\/peds.2007-1578","type":"journal-article","created":{"date-parts":[[2008,2,29]],"date-time":"2008-02-29T14:48:09Z","timestamp":1204296489000},"page":"e687-e692","source":"Crossref","is-referenced-by-count":146,"title":["Risk of Immune Thrombocytopenic Purpura After Measles-Mumps-Rubella Immunization in Children"],"prefix":"10.1542","volume":"121","author":[{"given":"Eric K.","family":"France","sequence":"first","affiliation":[{"name":"Department of Preventive Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Glanz","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Kaiser Permanente Colorado, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Xu","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Kaiser Permanente Colorado, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Hambidge","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Kaiser Permanente Colorado, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Kaiser Permanente Colorado, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve B.","family":"Black","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Marcy","sequence":"additional","affiliation":[{"name":"Center for Vaccine Research, Kaiser Permanente Southern California, Torrance, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Mullooly","sequence":"additional","affiliation":[{"name":"Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Group Health Cooperative, Group Health Center for Health Studies, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nordin","sequence":"additional","affiliation":[{"name":"Department of Vaccine Research, HealthPartners Research Foundation, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Belongia","sequence":"additional","affiliation":[{"name":"Epidemiology Research Center, Marshfield Clinic Research Foundation, Marshfield, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hohman","sequence":"additional","affiliation":[{"name":"Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of HIV\/AIDS Prevention"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Davis","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Vaccine Safety Datalink Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,3,1]]},"reference":[{"key":"2021120905501404600_R1","unstructured":"Institute of Medicine. Measles and mumps vaccines. In: Stratton KR, Howe CJ, Johnston RB, eds. Adverse Events Associated With Childhood Vaccines: Evidence Bearing on Causality. Washington, DC: National Academy Press;1994:118\u2013186"},{"key":"2021120905501404600_R2","doi-asserted-by":"crossref","unstructured":"Jadavji T, Scheifele D, Halperin S; Canadian Paediatric Society\/Health Canada Immunization Monitoring Program. Thrombocytopenia after immunization of Canadian children: 1992 to 2001. Pediatr Infect Dis J.2003;22(2):119\u2013122","DOI":"10.1097\/01.inf.0000048961.08486.d1"},{"key":"2021120905501404600_R3","doi-asserted-by":"crossref","unstructured":"Jonville-Bera A, Autret E, Galy-Eyraud, Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centers and Pasteur-Merieux serums et vaccins. Pediatr Infect Dis J1996;15(1):44\u201348","DOI":"10.1097\/00006454-199601000-00010"},{"key":"2021120905501404600_R4","doi-asserted-by":"crossref","unstructured":"Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J.1996;15(1):88\u201390","DOI":"10.1097\/00006454-199601000-00020"},{"key":"2021120905501404600_R5","doi-asserted-by":"crossref","unstructured":"Miller E, Waight P, Farrington P, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child.2001;84(3):227\u2013229","DOI":"10.1136\/adc.84.3.227"},{"key":"2021120905501404600_R6","doi-asserted-by":"crossref","unstructured":"Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopenic purpura. Br J Clin Pharmacol.2003;55(1):107\u2013111","DOI":"10.1046\/j.1365-2125.2003.01790.x"},{"key":"2021120905501404600_R7","doi-asserted-by":"crossref","unstructured":"Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics.1997;99(6):765\u2013773","DOI":"10.1542\/peds.99.6.765"},{"key":"2021120905501404600_R8","unstructured":"Chen RT. Safety of vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, PA: WB Saunders Company;1999:1144\u20131163"},{"key":"2021120905501404600_R9","doi-asserted-by":"crossref","unstructured":"Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics.1995;51(1):228\u2013235","DOI":"10.2307\/2533328"},{"key":"2021120905501404600_R10","doi-asserted-by":"crossref","unstructured":"Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol.1996;143(11):1165\u20131173","DOI":"10.1093\/oxfordjournals.aje.a008695"},{"key":"2021120905501404600_R11","doi-asserted-by":"crossref","unstructured":"Glanz JM, McClure DM, Xu S, et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemol.2006;59(8):808\u2013818","DOI":"10.1016\/j.jclinepi.2005.11.012"},{"key":"2021120905501404600_R12","doi-asserted-by":"crossref","unstructured":"Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics.2000;106(5). Available at: www.pediatrics.org\/cgi\/content\/full\/106\/5\/e62","DOI":"10.1542\/peds.106.5.e62"},{"key":"2021120905501404600_R13","unstructured":"Brighton Collaboration. Available at: www.brightoncollaboration.org\/intranet\/en\/index\/document_download.regdown.l2fJy2vZCY9NCM91ChmVyNjPz2H0B25Fz3jVDxbZl2LTCgXLBwvUDgf0Aw9Ux2DYB3vWCY9PDha-.html\/TP%20and%20ITP%20webdraft%2020041019.pdf?qualident=MainContentPar.0001.RegDownloadDocuments.0047.DownloadFile. Accessed December 22,2006"},{"key":"2021120905501404600_R14","doi-asserted-by":"crossref","unstructured":"Kuhne T, Buchanan GR, Zimmerman S, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the intercontinental childhood ITP study group. J Pediatr.2003;143(5):605\u2013608","DOI":"10.1067\/S0022-3476(03)00535-3"},{"key":"2021120905501404600_R15","doi-asserted-by":"crossref","unstructured":"Kuhne T, Imbach P, Bolton-Maggs PH, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet.2001;358(9299):2122\u20132125","DOI":"10.1016\/S0140-6736(01)07219-1"},{"key":"2021120905501404600_R16","doi-asserted-by":"crossref","unstructured":"Sutor AH, Harms A, Kaufmehl K. Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany. Semin Thromb Hemost.2001;27(3):253\u2013267","DOI":"10.1055\/s-2001-15255"},{"key":"2021120905501404600_R17","doi-asserted-by":"crossref","unstructured":"Rosth\u00f8j S, Hedlund-Treutiger I, Rajantie J, et al. Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children: a prospective Nordic study of an unselected cohort. J Pediatr.2003;143(3):302\u2013307","DOI":"10.1067\/S0022-3476(03)00245-2"},{"key":"2021120905501404600_R18","doi-asserted-by":"crossref","unstructured":"Agran PF, Anderson C, Winn D, Trent R, Walton-Haynes L, Thayer S. Rates of pediatric injuries by 3-month intervals for children 0 to 3 years of age. Pediatrics.2003;111(6 pt 1). Available at: www.pediatrics.org\/cgi\/content\/full\/111\/6\/e683","DOI":"10.1542\/peds.111.6.e683"},{"key":"2021120905501404600_R19","unstructured":"Centers for Disease control and Prevention. Impact of vaccines universally recommended for children: United States, 1990\u20131998. MMWR Morb Mortal Wkly Rep.1999;48(12):243\u2013248"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/3\/e687\/1123451\/zpe0030800e687.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/3\/e687\/1123451\/zpe0030800e687.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T23:42:56Z","timestamp":1639093376000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/3\/e687\/72855\/Risk-of-Immune-Thrombocytopenic-Purpura-After"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,1]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2008,3,1]]},"published-print":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-1578","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,1]]}}}